Human Monoclonal Folate Receptor Beta Antibody

Back to all technologies
Download as PDF
65627
Folic acid is a vitamin required for the synthesis of DNA nucleotide bases and is essential for proliferation of all cells. To take in folic acid, some cells express a folate receptor that binds folic acid very tightly and carries it into the cell via endocytosis. There are four types of folate receptors: alpha; beta; gamma; delta, and these receptors are preferentially overexpressed on cancer cells.

Purdue University researchers have developed a method for using a human monoclonal antibody against beta folate receptors. By targeting cancer cells and binding antibodies to the beta folate receptors on those cells, researchers can block some of the beta folate receptors on the cells. This lowers the amount of folic acid the cancer cell is receiving and prevents its rapid proliferation. By attaching chemical groups to the antibody, e.g. therapeutics or imaging agents, this approach can be used to potentially treat or identify cancers. It is particularly useful for targeting of chronic and acute leukemia, and has potential to treat these disorders, along with immunological conditions such as rheumatoid arthritis.

Advantages:
-Lowers the amount of folic acid cancer cells take in
-Potential cancer treatment
-Also treats inflammatory disorders
Apr 8, 2016
DIV-Patent
United States
9,963,505
May 8, 2018

Oct 27, 2014
CON-Patent
United States
9,914,773
Mar 13, 2018

Mar 8, 2013
CIP-Patent
United States
8,871,206
Oct 28, 2014

May 3, 2018
CON-Patent
United States
(None)
(None)

Mar 14, 2018
DIV-Patent
European Patent
(None)
(None)

Sep 9, 2011
PCT-Patent
WO
(None)
(None)

Sep 9, 2011
NATL-Patent
European Patent
(None)
(None)

Sep 9, 2010
Provisional-Patent
United States
(None)
(None)

(None)
NATL-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org